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Abstract
Genetic analysis of hepatitis B virus (HBV) frequently involves study of intra-host variants, identification of which is
commonly achieved using short regions of the HBV genome. However, the use of short sequences significantly limits
evaluation of genetic relatedness among HBV strains. Although analysis of HBV complete genomes using genetic cloning
has been developed, its application is highly labor intensive and practiced only infrequently. We describe here a novel
approach to whole genome (WG) HBV quasispecies analysis based on end-point, limiting-dilution real-time PCR (EPLD-PCR)
for amplification of single HBV genome variants, and their subsequent sequencing. EPLD-PCR was used to analyze WG
quasispecies from serum samples of patients (n=38) infected with HBV genotypes A, B, C, D, E and G. Phylogenetic analysis
of the EPLD-isolated HBV-WG quasispecies showed the presence of mixed genotypes, recombinant variants and sub-
populations of the virus. A critical observation was that HBV-WG consensus sequences obtained by direct sequencing of
PCR fragments without EPLD are genetically close, but not always identical to the major HBV variants in the intra-host
population, thus indicating that consensus sequences should be judiciously used in genetic analysis. Sequence-based
studies of HBV WG quasispecies should afford a more accurate assessment of HBV evolution in various clinical and
epidemiological settings.
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Introduction
Molecular characterization of hepatitis B virus (HBV) is critical
to the identification of viral factors that affect outcome of infection,
progression and severity of disease as well as responses to antiviral
suppression. The complex structure of the HBV genome
composed of overlapping and non-overlapping open reading
frames (ORFs) significantly constrains HBV evolution [1].
Moreover, the rate of mutation varies among the ORFs [2]. As
a result, sub-genomic regions do not reflect evolution of the entire
genome. However, genetic analysis of HBV usually involves the
study of short genomic regions [3,4], thereby impeding assess-
ments of HBV evolution [5].
Because of its high mutational rate [6], HBV persists as a large
set of closely related variants in infected hosts [7]. Analysis of the
genetic composition of the intra-host HBV population is
particularly critical to evaluating the emergence of vaccine-escape
and drug-resistant mutants. Conventional methods fail to detect
minority populations of drug-resistant viral quasispecies if they
represent less than 25% of the total sample virus population
[8,9,10]. Detailed study of the dynamics of viral variants persistent
in a given host has long been hampered by the poor sensitivity of
sequencing methods. Various approaches have been used to detect
mutant HBV populations, though seldom at the whole-genome
(WG) level [11,12]. Genetic cloning is a method of choice for
quasispecies assessment. However, it is applied to analysis of short
genomic fragments such as the reverse transcriptase (RT) domain
or a segment of the core ORF [13]. Furthermore, genetic cloning
assays for analysis of intra-host viral populations are time-
consuming, labor-intensive, costly and unsuitable for screening
large numbers of samples.
The advent of new technologies such as ultra-deep sequencing
using the 454 GS FLX sequencer, Illumina genome analyzer and
SOLiD sequencing have brought about a paradigm shift in virus
research [14,15,16]. Their use to sequence multiple genetic
variants in HIV [17,18] and the RT domain of HBV [19,20]
has been reported. However, because of the short read-lengths
generated by these technologies, their application is limited to
analysis of sub-genomic regions. Assembly of WG sequences for
individual viral variants is computationally extensive and is still
being developed [21]. Therefore, the information on the WG
quasispecies that can be currently obtained using these high-
throughput sequencing technologies is primarily in the form of
consensus WG sequences accompanied with information on the
frequency of nucleotides at polymorphic sites.
Here we report on the development and validation of an
automated, medium-throughput approach to WG-HBV sequenc-
ing. We had earlier found that end-point, limiting-dilution PCR
(EPLD-PCR) is efficient for quasispecies evaluation of sub-
genomic regions of hepatitis C virus [22] and HBV [23]. We
have also compared the post-PCR cloning and EPLD-PCR
protocols applied to intra-host HBV populations [24], and showed
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25232a superior sensitivity of EPLD-PCR in detecting HBsAg variants
present at frequency as low as 0.1% of the total viral population.
Accordingly, in this study, EPLD-PCR was adopted for separation
and sequencing of individual intra-host HBV WG variants.
Results
EPLD-PCR optimization
Using serum samples collected from patients with acute (n=8)
and chronic HBV infection (n=30), the performance of the EPLD-
PCR approach was compared to consensus PCR amplification.
First-round WG amplification was optimized using 4 different
primer sets. The primer pair 1801/1823 (WG-F1/R1, Table 1)
that amplified HBV genome with a 22-bp gap was a log more
sensitive than PCR using the other primer sets, 1798/1801, 1821/
1825 and 1849/1855, that amplified the HBV genome with 4, 5
and 7 bp overlap, respectively. If viral titer is not a limitation,
the overlap primers could be used for the first round WG
amplification, followed by nested PCR with additional two
overlapping fragments (F7F/R-1796F/2394R and F8F/R-
1176F/1829R). As our study samples included both high- and
low-titer samples, we consistently used the 1801/1823 (WG-F1/
R1) primer pair, followed by six overlapping nested fragments
(F1–F6), for all our analysis (Fig. 1). Detection sensitivity of this
approach was 5610
2 IU/ml using the World Health Organization
(WHO) HBV DNA international standard (NIBSC code: 97/656).
Three differentstrategieswere used to optimize the second-round
PCR: namely, (i) two overlapping fragments encompassing the
entire genome, (ii) six overlapping fragments of 600 bp each, and
(iii) nine overlapping fragments ranging from 350–550 bp. The first
set of primers by virtue of its size (.1.5 Kb) was not as sensitive as
the other two approaches, and also had the limitation of not being
conducive to real-time PCR amplification and sequencing. The
nine-PCR-fragment strategy frequently produced incomplete sets of
PCR fragments because of differential sensitivity of primers. The
six-PCR-fragment approach had a concordant sensitivity among
primer sets. Moreover, this strategy produced PCR fragments of
lengths that are conducive for the clonal selection process using
melt-curve analysis.Wetherefore usedthesixprimersetsforall WG
quasispecies amplification (Table 1, Fig. 1). Additionally, all second-
round PCR primers were tagged with sequences of the SP6- or T7-
promoters. The application of these tagged primers allowed for the
use of only 2 sequencing primers containing SP6 or T7 sequences
and for the application of another re-sequencing technology
MassArray MALDI-TOF mass spectrometry (Sequenom, Inc.,
San Diego, CA) in our laboratory [25]. The tagged primers did not
compromise the sensitivity of the protocol.
Validation of single-molecule amplification
For WG quasispecies analysis, EPLD-PCR was performed using
serially diluted DNA. At end-point dilution, the DNA target
Table 1. Primers used for HBV whole genome quasispecies
amplification.
Primers Sequence (59R39) Direction Nucleotide
1st round
PCR
WG-F1 TTTCACCTCTGCCTAATCATCT Forward 1823
WG-R1 CAGACCAATTTATGCCTACAGCCT Reverse 1801
WG-F2
* TTCATGTCCTACTGTTCAAGCCTC Forward 1849
WG-R2
* ACATGAACAAGAGATGATTAGGCAG Reverse 1855
WG-F3
* TTTTTCACCTCTGCCTAATCATCTC Forward 1821
WG-R3
* AAAAAGTTGCATGGTGCTGGTGAAC Reverse 1825
WG-F4
* CTGCGCACCAGCACCATGCAACTTTTTC Forward 1798
WG-R4
* CAGACCAATTTATGCCTACAGCCT Reverse 1801
Nested PCR
F1F TGTTCATGTCCCACTGTTCAA Forward 1847
F1R GGCGAGGGAGTTCTT Reverse 2394
F2F GACCACCAAATGCCCCTAT Forward 2298
F2R TCGGGAAAGAATCCCAGAGGAT Reverse 2933
F3F GGTCACCATATTCTTGGGAAC Forward 2821
F3R TGAGAGAAGTCCACCACGAGT Reverse 272
F4F CTAGGACCCCTGCTCGTGTT Forward 179
F4R CGAACCACTGAACAAATGGCACT Reverse 704
F5F GTATTCCCATCCCATCATCCTG Forward 599
F5R GCTAGGAGTTCCGCAGTATGG Reverse 1286
F6F GCCAAGTGTTTGCTGA Forward 1175
F6R GCCTACAGCCTCCTA Reverse 1788
F7F
* GGTCTGCGCACCAGCACCATG Forward 1796
F7R
* GGCGAGGGAGTTCTT Reverse 2394
F8F
* GCCAAGTGTTTGCTGAGGCA Forward 1176
F8R
* TGGTGAAAAAGTTGCATGGTGCTGG Reverse 1829
Note: Each nested primer also contained adaptor sequence tags for
sequencing purpose. The forward primers were tagged with SP6 sequence
(59CGATTTAGGTGACACTATAGAAGAGAGGCT39), and reverse primers with T7
sequence (59CAGTAATACGACTCACTATAGGGAGAAGGC39).
*Overlapping WG primers (WG-F2 to F4) when used in the first round PCR,
additional two nested primers - F7 and F8 are to be added.
doi:10.1371/journal.pone.0025232.t001
Figure 1. Flowchart of the HBV WG amplification process.
doi:10.1371/journal.pone.0025232.g001
Characterization of HBV Genome Quasispecies
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25232templates are distributed in a Poisson manner so that most
reactions (50% or more) do not amplify template molecules and
thus do not generate PCR products. The dilution that resulted in
positivity in three of six replicates was considered to be limiting,
and under such conditions, the positive reactions are most likely to
have been initiated from a single-template molecule. We have
shown earlier that the function of end-point limiting-dilution in the
EPLD-PCR is to limit the number of molecules to a small critical
number, from which only one molecule is stochastically amplified
in the PCR process [22]. Thus, it is not necessary to dilute
specimen down to a single DNA molecule in order to successfully
sample single sequence variants. Narrowing down to a minimum
pool of DNA molecules prior to PCR amplification is the very
important requirement of the technique. However, presence of a
pool, though a minimum pool, of HBV DNA molecules at the
end-point limiting-dilution generates a theoretical possibility for
amplification of more than one molecule during the first-round
PCR. In such a scenario, each of six nested PCR fragments has a
chance to be amplified from a different first-round WG product,
with the assembled WG sequence being composed of a mosaic of
fragments derived from different HBV genomes. Therefore, it is
important to confirm whether all six fragments amplified by nested
PCR are derived from the same, single WG DNA molecule
amplified in the first round.
To validate amplification of the final PCR products from a
single DNA molecule, we used first-round PCR products obtained
from a serum specimen containing two dominant HBV variants,
C2 and C21. These variants differed at two nucleotide positions in
the HBV S gene. These first-round PCR products containing
either C2 or C21 were each used to amplify the S gene in 35-40
independent nested PCR reactions. It was expected that the S-
gene sequences would belong to both C2 and C21 clones if each of
the two first-round products contained a mixture of clones, while
these sequences would be identical among all repeats obtained
from same first-round products if only a single clone was amplified
from a minimum pool of HBV WG DNA molecules at the end-
point limiting-dilution. As shown in Fig. 2, all repeats had identical
sequences consistent with the corresponding clone, thus strongly
confirming that each of the first- and second-round PCR products
was indeed amplified from a single C2 or C21 HBV DNA
template recovered from the serum specimen. Detection of
identical sequences among so many repeats from each first-round
PCR product emphasizes the fact that the nucleotide changes
observed between C2 and C21 variants are not random PCR
errors. The observed high reproducibility of sequences may be
attributed to the use of high-fidelity DNA polymerase incorporat-
ed in EPLD-PCR, which minimizes the PCR error rate and
improves accuracy of DNA amplification.
Since the EPLD-PCR assay requires 5610
2 IU/ml of HBV
DNA for amplification, this experiment provides an additional
proof of concept that the function of end-point limiting-dilution,
prior to the amplification process, is to limit the number of DNA
molecules to a small critical number, from which only one
molecule is then stochastically amplified in the first round PCR
(30). The first-round DNA enriched with this one molecule is
consequently amplified into overlapping six fragments, which are
therefore representative of a single HBV WG variant / template /
molecule.
Figure 2. Repeat amplification of the S-gene fragment from first round PCR products. Two WG first-round products (C2 and C21)
containing two nucleotide changes (indicated in red) were subjected to 40 independent nested PCR amplifications; a sample of 5 identical S-gene
sequences amplified from each clone is shown.
doi:10.1371/journal.pone.0025232.g002
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Variation in the number of complete WG clones amplified
depends on the viral load of the sample analyzed. For most
analyses, we aim at amplifying 50–60 clones per 100 reactions
(50% positivity). Fewer clones (,50 clones per 100 reactions) are
usually amplified from a sample with a low DNA viral load. On
the other hand, extensive end-point limiting-dilution is required to
achieve 50% positivity on some samples, which have a high viral
load (.10
6 IU/ml).
Among the 38 serum samples evaluated, about 50–60 clones
were amplified from high titer (.10
6 IU/ml) samples (n=9), 15–
45 clones from intermediate titer (5610
3 to 10
6 IU/ml) samples
(n=15), and 4–14 clones from low titer specimens (n=10) that
have DNA viral load in the range of 5610
2 IU/ml (the low end of
the WG assay sensitivity). Some low titer specimens tested by
EPLD-PCR were obtained after HBe-seroconversion. In very high
titer samples (.10
10 IU/ml, n=4), clones selected at 50%
positivity showed mixed peaks in the nested reaction. Amplicons
obtained at that dilution were usually discarded. Selection of
clones at 30–35% positivity is recommended for such specimens to
avoid mixed sequences. In high titer samples, all clones were
usually represented with a complete set of six second-round PCR
fragments. However, ,5–10% of clones failed to generate all six
fragments from the low-titer samples. Fragments 1 and 6 were
most frequently underrepresented.
Reproducible detection of intra-host HBV variants
To assess the reproducibility of assessment of intra-host viral
populations, EPLD PCR was repeated twice using 8 samples
representing high and low HBV loads. Fig. 3 shows phylogenetic
analysis of HBV-WG quasispecies amplified in two independent
batches (red and blue colored tips) from one high- and one low-
titer sample. A total of 69 clones were amplified from the high-titer
sample (Fig. 3a) and 14 from the low-titer specimen (Fig. 3b). As
illustrated in Fig. 3, regardless of the number of clones, the
quasispecies populations amplified in two independent batches are
comparable, and, further, the number of WG clones does not
directly correlate with diversity.
Application to different genotypes
The salient feature of this HBV WG EPLD-PCR approach is
that with the help of a single set of universal primers (Table 1),
HBV WG quasispecies can be efficiently amplified from major
genotypes (A–H). Among the 38 serum samples evaluated for WG
quasispecies, we found genotypes A (n=8), B (n=3), C (n=5), D
(n=16), E (n=3) and G (n=3). This primer set also amplified
HBV WG from specimens of patients infected with HBV
genotypes F (n=2) and H (n=2). However, because of the low
titer of the specimens from these genotypes available to this study,
only their consensus WG sequences were obtained. Phylogenetic
analyses of the WG quasispecies confirmed genotype classification.
Phylogenetic tree of WG quasispecies of six samples belonging to
genotypes A–E and G is shown in Fig. 4. The six-fragment WG-
assembly was successful in 96–98% of clones for all tested
genotypes, suggesting no genotype-specific bias for the universal
primers used in this study.
Detection of mixed genotypes
Fig. 5a shows phylogenetic analysis of WG quasispecies from an
HBV infected patient. The HBV WG consensus sequence
obtained by sequencing of PCR fragments directly amplified from
the serum specimen is shown in red, while WG quasispecies
obtained by the EPLD-PCR approach are presented as blue. The
consensus WG sequence from samples drawn at two time-points
from this patient belonged to genotype A. The EPLD-PCR
analysis of the quasispecies (blue) from the same patient not only
showed a cluster of quasispecies in close proximity to the two
consensus sequences, but also co-existence of another cluster
belonging to genotype G. It is conceivable that the use of universal
primers for consensus sequencing imposed a primer bias for
amplification of genotype A over G. However, the use of the
genotype G-specific primers for amplification still resulted in the
consensus sequence belonging to genotype A (data not shown).
Among all tested samples (N=38), we found mixed genotypes in
only two that showed genotype A after consensus WG sequencing,
while WG quasispecies belonged to genotypes A and G.
Detection of intra-host subpopulations
Fig. 5b shows phylogenetic tree of the HBV intra-host WG
variants belonging to genotype B (blue). The HBV WG consensus
sequence (red) was associated with one viral subpopulation, while
EPLD-PCR detected additional WG variants that belonged to two
genetically distant viral subpopulations. The consensus sequence
for the most part was in close proximity, but not identical to any of
Figure 3. Reproducibility of EPLD protocol for WG-HBV quasispecies amplification. Phylogenetic analysis of HBV-WG quasispecies
amplified in two independent batches (red and blue colored nodes) of the same high-titer (a) and low- titer (b) sample.
doi:10.1371/journal.pone.0025232.g003
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closest sequence to the consensus was at least one nucleotide
different.
Detection of recombination events
Subdivision of HBV quasispecies into subpopulations due to
recombination events involving a small fraction of the HBV intra-
host population frequently remains unnoticed because of limited
capacity of molecular technologies in identifying viral WG
quasispecies. Analysis of WG quasispecies from the patient co-
infected with genotypes A and G illustrated the capacity of the
technique developed in this study to detect and characterize inter-
genotypic recombination (Fig. 5c). Among all tested specimens
(n=38), we found this phenomenon only in one. The consensus
WG sequence belonging to genotype G (red) revealed no
recombination event in the complete-length genome. But a closer
examination of the intra-host WG population indicated presence
of two variants that were distant from the major subpopulation
(blue). SimPlot and bootscan analyses revealed that these two
clones were hybrids generated via inter-genotypic recombination
between genotypes G and A. One genotype G recombinant
variant contained the genotype A sequences at nucleotide position
704–1167 (S and Polymerase region) and the other variant at
2005–2411(Core region). In order to show that the recombination
event identified through the EPLD-PCR was not due to PCR
introduced errors, we used genotype A and G specific primers on
(i) genotype A alone and G alone samples independently, (ii) also
physically mixing these 2 genotype samples in different ratios, (iii)
specimen shown in Fig 4c, that shows recombination (A and G)
Figure 4. WG-HBV quasispecies amplification of different
genotypes. HBV WG was amplified from samples belonging to
genotypes A–G using a universal set of primers. Maximum likelihood
tree shows WG quasispecies of genotypes A– E and G. Each cluster in
the tree is the WG quasispecies of an individual patient belonging to
one genotype.
doi:10.1371/journal.pone.0025232.g004
Figure 5. Detection of co-infections, subpopulations and recombination. (a) Maximum likelihood trees of HBV-WG quasispecies (blue) and
consensus WG sequences from a single patient (viral titer of 10
6 IU/ml). HBV quasispecies belong to genotypes A and G, while consensus WG
sequences (red) obtained at two time-points belong to genotype A. (b) Maximum likelihood tree of HBV-WG quasispecies from a genotype B infected
patient (viral titer of 10
5 IU/ml). Consensus sequence shown in red belongs to a single HBV subpopulation, while the WG quasispecies shown in blue
segregate into 2 subpopulations. (c) Maximum likelihood tree of WG quasispecies (blue) sampled from a patient (viral titer of .10
6 IU/ml) infected
with genotype G and recombinant genotype G/A variants. Consensus sequence (red node) belongs to genotype G. Two HBV WG clones, that are
genetically distant from the main cluster of genotype G variants, contain genomic regions belonging to genotype A.
doi:10.1371/journal.pone.0025232.g005
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but no recombination. We unanimously saw that physical mixing
of the two genotypes, or mixed genotypes naturally occurring in an
infection, did not necessarily give rise to any recombination due to
the PCR process.
Distribution of polymorphic sites along the genome
HBV evolution and intra-host population structure are
frequently monitored using short regions of the HBV genome
such as the S gene [3]. However, because data on the HBV WG
quasispecies are very limited, it is not clear whether quasispecies of
short regions adequately reflect intra-host HBV evolution. The
distribution of polymorphic sites along the HBV WG quasispecies
is shown in Fig. 6. Alignment of all WG sequences from
independent samples belonging to different genotypes (B, D, E
and G) showed the presence of nucleotide changes occurring
throughout the entire genome, with regions of apparent
substitution clustering including the RT domain, and the core
and spacer regions (Fig. 6a). Furthermore, WG quasispecies from
genetically close HBV variants of genotype D identified in patients
(samples 1–4) linked by horizontal transmission showed a similar
profile (Fig. 6b). These observations suggest that nucleotide
variations occur across the entire genome within and between
genotypes, and there is no particular short sequence that could be
analyzed independently to accurately evaluate viral evolution.
Diversity of HBV quasispecies population
Quasispecies diversity of lamivudine-naı ¨ve and -treated indi-
viduals were evaluated. The star-like phylogeny reflects lower
genetic diversity of the complete genome in naı ¨ve compared to
treated subject (Fig. 7). Unlike the naı ¨ve case, the consensus
sequence of the treated subject was not reflective of the entire viral
population. Nucleotide diversity of the treated group (n=8) was
on average 3 fold greater than in the naı ¨ve group (n=8), the
difference being significant (p=0.0194).
Discussion
Understanding the evolution of HBV genome, and identifying
mutations that determine phenotypic variations in different clinical
and epidemiological settings are important for management of
HBV drug resistance and vaccine escape. In this study, we
describe for the first time the use of the EPLD-PCR approach for
analyzing viral quasispecies of the HBV genome of different
genotypes. WG quasispecies information obtained using this
approach is derived from independent DNA molecules rather
than from consensus sequence of all intra-host variants, as is the
case with deep sequencing approaches [19,20]. This EPLD-PCR
novel approach provides important information for delineating the
dynamics of the intra-host viral population and understanding the
genetic linkage among genomic sites.
The main features of the EPLD-PCR-based approach to HBV
WG quasispecies sequencing are that it: (i) is real-time-based which
thereby circumvents the need for post-PCR cloning, (ii) has high
sensitivity, (iii) has minimal PCR-prone errors due to the use of
high-fidelity enzyme,(iv)uses the same PCRconditions for all sets of
PCR primers; (v) has equal sensitivity for all six nested primers, (vi)
incorporates tagged nested primers allowing use of only 2 sequence
primers, and (vii) is adaptable to automation so reducing cost,
hands-on time and probability of cross-contamination.
It is frequently assumed that the end-point limiting-dilution
protocol for amplification of individual genetic variants depends
on dilution down to a single molecule [26,27]. Recently, we have
shown that this dilution is rather determined by the probability of
amplification of only a single molecule from a pool of molecules.
The minimal size of the pool is defined by the efficiency of PCR
amplification, with less efficient PCR conditions requiring a larger
pool of molecules for single-molecule amplification [22]. This
finding suggests that, although amplification of long DNA
molecules like HBV WG has low probability of being achieved
from a single molecule of the HBV genome, a single HBV genome
variant can still be amplified from a small pool of DNA molecules
at that dilution. Such a principle was applied in this method
developed for HBV WG quasispecies analysis.
To improve efficacy of quasispecies detection and sequencing,
we devised a second-round PCR using 6 sets of PCR primers for
amplification of small overlapping fragments. Theoretically, such
amplification protocol may result in assembly of mosaic WG
sequences if some of 6 PCR fragments were derived from different
HBV variants. However, the experiments conducted in this study
showed that there is a very low chance of amplifying a mixture of
HBV WG at the end-point. This observation strongly validates the
use of 6 PCR fragments in the second-round amplification for
HBV WG quasispecies analysis. This is also proof of concept that
the amplification of HBV WG at limiting dilution is narrowed
down to a single molecule randomly selected from a small pool of
DNA molecules, while the direct PCR amplification for consensus
sequencing uses a mixture of DNA molecules. Such consideration
underlies why consensus sequence-based methods are only capable
of detecting substitutions present in viral quasispecies with a
prevalence of .20% of the total HBV population [28].
Amplification of WG quasispecies through EPLD appears to
have the propensity to recover both the commonly occurring
genomes, and those that do not belong to the main lineage.
Detection and molecular characterization of the viral population,
including minor variants, at the WG level is important for
understanding the development of drug resistance. For example, it
is known that minority drug-resistant human immunodeficiency
virus variants arising during therapy are significantly relevant
clinically, as they can quickly grow out when subjected to the
selective pressure exerted by the drug to then become dominant,
so leading to treatment failure [29,30]. Many published data have
shown that the appearance of resistance mutations may precede
the increase in viral load (virological resistance) by several months
[31] and could be a prognostic marker for the occurrence of viral
breakthrough. However, since WG sequences of intra-host HBV
variants are only infrequently available, changes in the genetic
structure of the intra-host HBV populations under the selection
pressure of therapeutic treatment are usually assessed using
subgenomic fragments. A significant conservation of the HBV
genome limits genetic variability of subgenomic regions [3,4], thus
preventing the accurate reconstruction of intra-host HBV
populations. Fig. 7 shows changes in the genetic composition of
the intra-host HBV population after the therapeutic treatment.
Although application of drugs inhibiting viral replication in treated
patients seems to provide the strongest selection pressure, HBV
should be under many other selection pressures related to the
natural course of chronic infection such as neutralizing immune
responses. Interaction among different selection forces may affect
the outcome of therapy and requires a thorough evaluation, which
can be achieved through analysis of WG HBV sequences. This
analysis is key to the identification of epistatic connectivity among
genomic sites [32], and to relating this connectivity to outcomes of
therapeutic treatment [5,33]. Only a limited number of HBV
mutations selected during antiviral treatment have been well
characterized, and the diagnostic and public health implications of
other mutations occurring at the whole genome level need further
investigation.
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25232Figure 6. Distribution of mutations along the HBV genome. (a) Polymorphic positions along the HBV WG quasispecies obtained from
4 patients infected with different HBV genotypes (viral titer of 10
3–10
6 IU/ml). (b) Sliding window analysis of polymorphic regions identified among
genotype D variants (each shown with different color) implicated into a horizontal transmission among 4 patients (samples 1–4; viral titer of
10
4–10
6 IU/ml).
doi:10.1371/journal.pone.0025232.g006
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quasispecies is also important for the identification and evaluation
of recombination events. HBV recombination has been frequently
detected during co-infection of hosts with more than one HBV
genotype, presenting an additional source of variability in HBV
genome [34,35]. In the present study, we have tested HBV WG
sequences using SIMPLOT for the detection of recombination
and for mapping exact recombination points. Bootscan analysis of
one study patient indicated that recombination emerged in the
core and RT gene. It has been reported that the sites of
recombination appeared different in each variant, suggesting that
recombinant variants are subjected to selection, and only one or a
few variants ultimately become dominant [36]. The ability of
EPLD-PCR analysis demonstrated here in identifying co-infection,
viral sub-populations and recombination events substantiates the
versatility of this approach for HBV WG quasispecies analysis.
A critical observation made in this study was that HBV-WG
consensus sequences obtained by direct sequencing of PCR
fragments without EPLD are not always identical to the major
HBV variants in the intra-host population. In some cases, HBV
consensus sequences were found to be different from the closest
intra-host HBV variants at 1–2 genomic sites. This difference
might be attributed to the complex pool of HBV DNA molecules
present in the sample and the stochastic nature of PCR. Variation
in amplification of different molecular species from the sample
among 6 PCR fragments used in the protocol for consensus
sequencing may result in reconstruction of hybrid WG sequences.
This is overcome in the EPLD process as the amplification is
limited to a single or minimal number of DNA molecules. The
observation of the discrepancy between the consensus sequences
and intra-host HBV variants indicates that WG consensus
sequences should be judiciously used in genetic analysis.
Sequence-based studies of HBV WG quasispecies should afford
a more accurate assessment of HBV evolution in various clinical
and epidemiological settings.
The data presented here project the strategy of amplifying full-
length HBV DNA quasispecies with minimal distortion using
EPLD approach. Unlike cloning approach where clonal selection
is performed after PCR amplification, EPLD-PCR introduces the
least PCR errors as DNA is diluted ahead of any amplification
process, thereby minimizing template jumping, allelic preference,
etc. There may be still concerns about primer bias and/or
mismatches with at least some archived HBV sequences which
might limit the outcome of their analyses. However, any
improvement to the current methodology, such as using more
efficient DNA polymerases (phusion DNA polymerase), can be
improvised to minimize the PCR-prone errors.
In comparison to ultra-deep sequencing technologies, the EPLD
approach generates fewer sequences. However, the EPLD
approach readily generates HBV WG sequences. We and others
have observed that assembly of such long sequences for individual
variants from short reads produced by the ultra-deep sequencing
technologies generates extremely challenging computational tasks
[14,21]. Additionally, the EPLD approach does not require any
additional equipment besides conventional equipment for PCR
and sequencing that is commonly available in many molecular
laboratories, nor do the data generated require extensive
computational assembly. Thus, the novel EPLD PCR-based
technique described here for sequencing of individual HBV
complete genome variants from a single DNA molecule is
conveniently amenable to HBV WG quasispecies analysis, thereby
allowing in-depth characterization of intra-host HBV populations,
detection of recombination events and evaluation of epistatic
connectivity along the HBV genome that facilitates investigation of
genomic co-evolution in clinical and epidemiological settings.
Materials and Methods
Study samples
Randomly selected serum samples were collected from patients
with acute and chronic HBV infection (n=38) identified in the
course of transmission and surveillance studies carried out by the
Centers for Disease Control and Prevention, Atlanta, GA.
Informed consent had been obtained from all participants and
ethical approvals were granted by the CDC ethics review board.
Samples were tested for: antibodies to hepatitis C virus (Ortho
HCV ELISA 3.0; Ortho-Clinical Diagnostics); antibodies to
HIV-1 (Vironostika HIV-1 MicroELISA System; bioMerieux);
Figure 7. Diversity in naive and treated individuals. Phylogenetic trees of HBV-WG quasispecies (blue) and consensus sequences (red) from:
(a) a treatment-naı ¨ve patient (viral titer 210
3 IU/ml) and (b) a lamivudine-treated patient (viral titer 210
6 IU/ml).
doi:10.1371/journal.pone.0025232.g007
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B core antigen(anti-HBc; ETI-AB-COREK PLUS; DiaSorin), IgM
anti-HBc (ETI-CORE-IgMK PLUS; DiaSorin), hepatitis B surface
antigen (HBsAg; HBsAg EIA 2.0; Bio-Rad), hepatitis B surface
antibody (anti-HBs; ETI-AB-AUK PLUS; DiaSorin), hepatitis B e
antigen(HBeAg;ETI-EBKPLUS;DiaSorin),hepatitisBeantibody
(anti-HBe; ETI-AB-EBK PLUS; DiaSorin), and HBV DNA
concentration (HBV ASR; Abbott Molecular). Samples from
HBsAg-positive patients were analyzed for HBsAg subtype by an
enzyme immunoassay [37].
Nucleic acid extraction
Total nucleic acids were isolated from all serum samples using
the robotic Roche MagNA Pure LC system (software version
3.0.11) and the MagNA Pure LC Total Nucleic acid isolation kit
(Roche Diagnostics GmbH, Mannheim, Germany), and eluted in
50 ul of lysis buffer according to the manufacturer’s instructions.
Real time PCR
First-round WG PCR was conducted using the GeneAmpH
PCR system 9700 (Applied Biosystem) incorporating the Expand
High-Fidelity PCR kit (Roche) with the 1823/1801 primer pairs
(Table 1). The cycling conditions were: 94uC/39, 10 cycles of
94uC/200, 55-45uC/300 with a step down of 1uC/cycle, and
extension 68uC/49, followed by 35 cycles of 94uC/200,4 5 uC/300,
68uC/49 increase elongation time 10 sec/cycle up to 7.20 min,
followed by a final elongation 68uC/109. Five ul of the extracted
DNA (including direct or log diluted DNA) is used per reaction /
50 ul reaction volume of the 1 st round PCR components which
includes 10X buffer containing Mg2+ (5 ul), 10 mM each dNTP
mix (1 ul), expand high-fidelity enzyme (0.5 ul of 3.5 U/ul) and
primers (1 ul of 50 uM each). For the nested PCR, 1 to 2 ul of the
first round product is used. For real-time nested PCR, six sets of
overlapping nested primers were used (Table 1, Fig. 1). Primers
were designed using multiple standard parameters such as
temperature, GC content, hairpin loops, dimer formation, etc.,
as implemented in PrimerSelect from the Lasergene DNA and
Protein analysis software (version 7.0, DNASTAR Inc., Madison,
WI.). The PerfeCTa SYBR FastMix chemistry (Quanta BioSci-
ences, Gaithersburg, MD) or Lightcycler Fast start DNA Master
+
Sybr Green kit (Roche, Applied Sciences, Indianapolis, IN) was
used for second-round amplification, and run on LC480 real-time
instrument (Roche) or Stratagene Mx3005P instrument (Strata-
gene, La Jolla, CA). The PCR conditions were: 95uC/109,9 5 uC/
300,5 5 uC/19,7 2 uC/320 for 40 cycles, and followed by melt curve
cycle of 95uC/19,8 0 uC/300,9 5 uC/300. The nested PCR reaction
includes 4 ul of Fast start DNA Master
+ Sybr mix, 1 ul each of
15 uM primers, 1 st round PCR product 1–2 ul and make up
volume to 20 ul.
For consensus WG sequencing, extracted DNA was directly
used in the 1
st round WG amplification followed by nested PCR of
six overlapping fragments. For WG quasispecies analysis, EPLD-
PCR was performed using serially diluted DNA [22]. The end-
point was found by the ability to amplify the 441-bp amplicon
containing the a determinant of the S gene (Primer 4) in a nested
PCR in 45–50% of the reactions. WG clones were identified by
melting curve analysis using the LightCycler
H 480 Roche software
version 1.5.0.SP3, following which the other five overlapping
primer sets encompassing the rest of the genome were amplified by
nested real-time PCR. The limiting-dilution that resulted in
positivity in three out of six replicates was considered to be the one
that was limiting. For each isolate, 96 EPLD amplification
reactions were carried out to obtain approximately 48 clones per
sample; the exact number varied depending on the viral titer. The
setting up of all reactions for PCR, clean up, selection of clones
and dilutions of the products for sequencing were performed using
Biomek 3000 robotic station (Beckman-Coulter, Completeerton,
CA). About 50–60 WG clones were amplified per sample, where
the number of clones amplified depends on the viral titer.
Sequencing
The nested primer sequences contain SP6 or T7 promoter and
enhancer sequences at the 59-ends of the specific primers to enable
convenient universal sequencing of all six fragments of the HBV
WG. Amplicons were subjected to standard di-deoxy termination
sequencing following the recommended by Applied Biosystems
BigDyeV3.1 protocol.
Genetic Analysis
Sequence electrophoregrams were initially analyzed and edited
using SeqMan and MegAlign programs from the Lasergene DNA
and Protein analysis software (version 7.0, DNASTAR Inc.,
Madison, WI.). Multiple sequence alignment and evolutionary
distances analysis were performed in Accelrys GCG, Version 11.0
(Genetic Computer Group, Accelrys Inc., San Diego, CA). HBV
genotypes were classified based on the S sequence, and confirmed
with WG sequences by comparing each sequence with published
referencesequencesfromGenBank.Thenucleotidediversity[38] of
each sample was calculated using the program ARLEQUIN [39].
Phylogenetic analysis
Maximum likelihood trees. The program ModelTest [40]
was used to establish the best model of RNA substitution for our
HCV data. The GTR model was chosen to create maximum
likelihood trees (ML) [41] using the program HyPHY [42]. An
initial tree was created using the neighbor-joining approach [43], a
search in the tree space was performed using nearest neighbor
interchange branch on the tree until no further likelihood score
improvements could be made.
Detection of inter-genotypic recombination
Recombination was examined in the WG sequences using
bootscan in SimPlot (ver. 3.5.1) [44]. Reference sequences for
HBV genotypes A to H were retrieved from GenBank, and
sequences with recombinant fragments were removed from this
analysis. In each case, sequence fragments of 200 bases
incrementing by 20 bases, with 100 bootstrap replicates, were
compared with consensus sequences of the human HBV
genotypes.
Author Contributions
Conceived and designed the experiments: SR YEK. Performed the
experiments: SR XZ HT LMGR JD. Analyzed the data: SR DSC GX.
Contributed reagents/materials/analysis tools: SR YEK. Wrote the paper:
SR YEK.
References
1. MizokamiM, OritoE,OhbaK, IkeoK,LauJY,etal. (1997) Constrainedevolution
with respect to gene overlap of hepatitis B virus. J Mol Evol 44 Suppl 1: S83–90.
2. Zhou Y, Holmes EC (2007) Bayesian estimates of the evolutionary rate and age
of hepatitis B virus. J Mol Evol 65: 197–205.
3. Cassino L, Laufer N, Salomon H, Campos R, Quarleri J (2009) Hepatitis B
precore/core promoter mutations in isolates from HBV-monoinfected and
HBV-HIV coinfected patients: a 3-yr prospective study. J Clin Virol 46:
354–359.
Characterization of HBV Genome Quasispecies
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e252324. Wang F, Wang H, Shen H, Meng C, Weng X, et al. (2009) Evolution of hepatitis
B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis
B virus treated with sequential monotherapy and add-on nucleoside/nucleotide
analogues. Clin Ther 31: 360–366.
5. Khudyakov Y (2010) Coevolution and HBV drug resistance. Antivir Ther 15:
505–515.
6. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V (2006) Mutations
affecting the replication capacity of the hepatitis B virus. J Viral Hepat 13:
427–434.
7. Pawlotsky JM (2005) The concept of hepatitis B virus mutant escape. J Clin Virol
34 Suppl 1: S125–129.
8. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, et al. (2003) Resistance to
adefovir dipivoxil therapy associated with the selection of a novel mutation in the
HBV polymerase. Gastroenterology 125: 292–297.
9. Osiowy C, Giles E (2003) Evaluation of the INNO-LiPA HBV genotyping assay
for determination of hepatitis B virus genotype. J Clin Microbiol 41: 5473–5477.
10. Zoulim F (2006) New nucleic acid diagnostic tests in viral hepatitis. Semin Liver
Dis 26: 309–317.
11. Bai YJ, Zhao JR, Lv GT, Zhang WH, Wang Y, et al. (2003) Rapid and high
throughput detection of HBV YMDD mutants with fluorescence polarization.
World J Gastroenterol 9: 2344–2347.
12. Hussain M, Chu CJ, Sablon E, Lok AS (2003) Rapid and sensitive assays for
determination of hepatitis B virus (HBV) genotypes and detection of HBV
precore and core promoter variants. J Clin Microbiol 41: 3699–3705.
13. Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, et al. Evolution of full-
length HBV sequences in chronic hepatitis B patients with sequential lamivudine
and adefovir dipivoxil resistance. J Hepatol 52: 478–485.
14. Shendure J, Ji H (2008) Next-generation DNA sequencing. Nat Biotechnol 26:
1135–1145.
15. Harismendy O, Frazer K (2009) Method for improving sequence coverage
uniformity of targeted genomic intervals amplified by LR-PCR using Illumina
GA sequencing-by-synthesis technology. Biotechniques 46: 229–231.
16. Lao KQ, Tang F, Barbacioru C, Wang Y, Nordman E, et al. (2009) mRNA-
sequencing whole transcriptome analysis of a single cell on the SOLiD system.
J Biomol Tech 20: 266–271.
17. Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, et al. (2007) DNA bar
coding and pyrosequencing to identify rare HIV drug resistance mutations.
Nucleic Acids Res 35: e91.
18. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007)
Characterization of mutation spectra with ultra-deep pyrosequencing: applica-
tion to HIV-1 drug resistance. Genome Res 17: 1195–1201.
19. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, et al.
(2009) Ultra-deep pyrosequencing of hepatitis B virus quasispecies from
nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients
and NRTI-naive patients. J Infect Dis 199: 1275–1285.
20. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, et al. (2009) Use
of massively parallel ultradeep pyrosequencing to characterize the genetic
diversity of hepatitis B virus in drug-resistant and drug-naive patients and to
detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol
83: 1718–1726.
21. Sundquist A, Ronaghi M, Tang H, Pevzner P, Batzoglou S (2007) Whole-
genome sequencing and assembly with high-throughput, short-read technolo-
gies. Plos ONE 2: e484.
22. Ramachandran S, Guoliang X, Ganova-Raeva L, Williams I, Khudyakov Y,
et al. (2008) End point limiting dilution real time PCR assay for evaluation of
HCV quasispecies in serum. J Virol Meth 151: 217–224.
23. Forbi JC, Vaughan G, Purdy MA, Campo DS, Xia GL, et al. (2010) Epidemic
history and evolutionary dynamics of hepatitis B virus infection in two remote
communities in rural Nigeria. Plos ONE 5: e11615.
24. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, et al. (2002) Genetic
variation of hepatitis B surface antigen coding region among infants with chronic
hepatitis B virus infection. J Med Virol 68: 319–327.
25. Ganova-Raeva L, Ramachandran S, Honisch C, Forbi JC, Zhai X, et al. (2010)
Robust hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol 48:
4161–4168.
26. Kraytsberg Y, Khrapko K (2005) Single-molecule PCR: an artifact-free PCR
approach for the analysis of somatic mutations. Expert Rev Mol Diagn 5:
809–815.
27. Blaak H (2005) Isolation of human immunodeficiency virus type 2 biological
clones from peripheral blood lymphocytes. Methods Mol Biol 304: 95–112.
28. Pallier C, Castera L, Soulier A, Hezode C, Nordmann P, et al. (2006) Dynamics
of hepatitis B virus resistance to lamivudine. J Virol 80: 643–653.
29. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C,
Kantipong P, et al. (2004) Intrapartum exposure to nevirapine and subsequent
maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med
351: 229–240.
30. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple,
linked human immunodeficiency virus type 1 drug resistance mutations in
treatment-experienced patients are missed by standard genotype analysis. J Clin
Microbiol 43: 406–413.
31. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, et al. (2005)
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing
genotypic resistance to lamivudine. Hepatology 42: 1414–1419.
32. Campo D, Dimitrova Z, Mitchell R, Lara J, Khudyakov Y (2008) Coordinated
evolution of the hepatitis C virus. Proc Natl Acad Sci USA 105: 9685–9690.
33. Aurora R, Donlin MJ, Cannon NA, Tavis JE (2009) Genome-wide hepatitis C
virus amino acid covariance networks can predict response to antiviral therapy
in humans. J Clin Invest 119: 225–236.
34. Bollyky PL, Rambaut A, Harvey PH, Holmes EC (1996) Recombination
between sequences of hepatitis B virus from different genotypes. J Mol Evol 42:
97–102.
35. Morozov V, Pisareva M, Groudinin M (2000) Homologous recombination
between different genotypes of hepatitis B virus. Gene 260: 55–65.
36. Garmiri P, Loua A, Haba N, Candotti D, Allain JP (2009) Deletions and
recombinations in the core region of hepatitis B virus genotype E strains from
asymptomatic blood donors in Guinea, west Africa. J Gen Virol 90: 2442–2451.
37. Swenson PD, Riess JT, Krueger LE (1991) Determination of HBsAg subtypes in
different high risk populations using monoclonal antibodies. J Virol Methods 33:
27–38.
38. Nei M (1987) Molecular evolutionary genetics. New York: Columbia University
Press.
39. Schneider S, Roessli D, Excoffier L (2000) ARLEQUIN version 2000: Software
for population genetic data analysis.
40. Posada D, Crandall K (1998) Modeltest: testing the model of DNA substitution.
Bioinformatics 14: 817–818.
41. Felsenstein J (1981) Evolutionary trees from DNA sequences: a maximum
likelihood approach. J Mol Evol 17: 368–376.
42. Kosakovsky S, Frost S, Muse S (2005) HyPhy: hypothesis testing using
phylogenies. Bioinformatics 21: 676–679.
43. Saitou N, Nei M (1987) The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol Biol Evol 4: 406–425.
44. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, et al. (1999)
Full-length human immunodeficiency virus type 1 genomes from subtype C-
infected seroconverters in India, with evidence of intersubtype recombination.
J Virol 73: 152–160.
Characterization of HBV Genome Quasispecies
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25232